Longeveron Rights Offering Subscription Period Begins
MIAMI, Aug. 22, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or…
News
Reflect Scientific Secures $200,000 Order from Prominent Bio-Pharma Client for Blast Freezers
OREM, Utah, Aug. 22, 2023 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (Symbol: RSCF), a leading…
Longeveron Rights Offering Subscription Period Begins
MIAMI, Aug. 22, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or…
PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan
REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT…
PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan
REDWOOD CITY, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT…
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
– Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in…
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
– Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in…
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria
60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035…
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria
60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035…
Vincerx Pharma Announces FDA Clearance of IND for VIP943
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate…
Vincerx Pharma Announces FDA Clearance of IND for VIP943
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate…
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
BEDMINSTER, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE American: MTNB), a clinical-stage…
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
BEDMINSTER, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE American: MTNB), a clinical-stage…
Kane Biotech to Release Second Quarter 2023 Financial Results on Aug 29, 2023 – Conference Call to Follow
WINNIPEG, Manitoba, Aug. 22, 2023 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the…
Kane Biotech to Release Second Quarter 2023 Financial Results on Aug 29, 2023 – Conference Call to Follow
WINNIPEG, Manitoba, Aug. 22, 2023 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the…
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
Presentations Highlight New Data on Diagnostic Accuracy and Novel Biomarkers of Disease Severity in Multiple…
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders
Presentations Highlight New Data on Diagnostic Accuracy and Novel Biomarkers of Disease Severity in Multiple…
Spectral Medical Inc. Announces Upsizing of Previously Announced Bought Deal Convertible Note Financing to C$5.5M
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR…
Spectral Medical Inc. Announces Upsizing of Previously Announced Bought Deal Convertible Note Financing to C$5.5M
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR…
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
CAMBRIDGE, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage…